AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02189018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad lib activity at home
Description: Ad lib activity at home
Study NCT02873572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: step 1: online assessment
Description: Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
Study NCT02873572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: step2: biomarkers of gamblers/gamers
Description: For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~* psychiatric assesment and~* registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015).
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozanimod
Description: ozanimod
Study NCT04546516 — intervention group
Intervention type: DEVICE
Intervention: HYAcorp Lips and HYAcorp Face
Description: Dermal filler injection to different facial areas
Study NCT02599090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle.
Study NCT01735968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST571 + BYL719
Description: Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
Study NCT02266290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: taping of ankle sprain
Description: All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
Study NCT02266290 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: taping of ankle sprain
Description: All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
Study NCT02266290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sport tex® kinesiotape
Study NCT02266290 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pretape Cramer®
Study NCT00317200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
Study NCT00317200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
Study NCT03794661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinician programmer electrode screening mode tool
Description: Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
Study NCT01573767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
Study NCT01573767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
Study NCT01573767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder during treatment period
Study NCT01573767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilanterol
Description: subjects will recieve 4 weeks via NDPI during treament period
Study NCT02004899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
Study NCT02004899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
Study NCT03175692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Exome Sequencing
Description: Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
Study NCT00527644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 5mm spring clip
Description: Microline Pentax 5mm Visu-Loc Clip Applier
Study NCT02939027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Brachytherapy (6,1 Gy)
Description: A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
Study NCT02939027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Brachytherapy (7 Gy)
Description: A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
Study NCT04175782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) protocol
Description: Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results
Study NCT02599597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-assisted iCBT
Description: 13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
Study NCT02599597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly screening with feedback
Description: Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
Study NCT02599597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly screening with feedback
Description: Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
Study NCT01130519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Commercially available. Administered by intravenous infusion.
Study NCT01130519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Commercially available. Administered orally.
Study NCT03566875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with the Stryker's MAKO™ system
Description: The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.
Study NCT03566875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with mechanical ancillary
Description: The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
Study NCT03912532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Description: NGM282
Study NCT03912532 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for NGM282
Study NCT00307632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norelgestromine (NLGM)/ethinyl estradiol (EE)
Description: Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
Study NCT01972451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with enhanced dye
Study NCT01972451 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy with enhanced dye
Study NCT00707902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine/lidocaine
Study NCT00707902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: echinacea/sage
Study NCT01250132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological and behavioral explorations
Description: Blood dosages:~* biochemistry~* pituitary gland~* somatotropic axis~* corticotropic axis~* gonadotropic axis~* thyrotropic axis~* antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)
Study NCT01328548 — intervention group
Intervention type: DRUG
Intervention: Zostavax
Study NCT01440140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
Study NCT01440140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional insulin pump delivery
Description: Subcutaneous delivery of Novorapid insulin according to usual pump regime
Study NCT04682262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical dilatation
Description: Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
Study NCT02987972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Lot 1
Description: Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
Study NCT02987972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Lot 2
Description: Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
Study NCT02987972 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
Study NCT01149421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered as a subcutaneous injection once weekly for 26 weeks
Study NCT01149421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a subcutaneous injection once weekly for 26 weeks
Study NCT05909813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Piano Keyboard Instruction
Description: During weeks two through seven, participants will receive a once a week, hour long, in-person individualized piano keyboard instruction as follows:~1. Warm-up~   1. Scales and Chords: Consisting of scales on seven major keys (C, D, E, F, G, A and B), chord progressions on I, IV, V, I. Two different keys will be learned every week.~  2. 5-finger exercises will be completed four times per week.~2. Piano Theory and Music~   1. Piano Theory: Playing through Alfred's Basic Adult All-in-One Course, Book 1, to be completed at the ability level of participant, with a least two new pages per lesson.~  2. Chosen Piece: Playing through an instrumental piece chosen by the participant.~Participants will be asked to practice homework from this lesson daily for 20 minutes per day, until their next weekly lesson.
Study NCT01725932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT based Self Help
Description: Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
Study NCT04615806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green solution
Description: ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
Study NCT03043157 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rocuronium
Description: intravenous rocuronium infusion
Study NCT02718183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)
Description: bleaching teeth gel to intracameral use.
Study NCT02718183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).
Description: bleaching teeth gel to intracameral use.
Study NCT06060106 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Description: The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.
Study NCT06060106 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
Study NCT02286648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: pulpotomy with formocresol
Study NCT02286648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: pulpotomy with MTA
Study NCT01560533 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interviews
Description: Interviews will be done with patients
Study NCT00846703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-mercaptopurine, Methotrexate
Description: 6-mercaptopurine p.o. qd~Methotrexate p.o. qw
Study NCT00846703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
Description: (1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)
Study NCT02549976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal MRI
Description: Abdominal MRI to realize within 4 months following inclusion
Study NCT02549976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper endoscopy
Description: Upper endoscopy to realize within 4 months following inclusion
Study NCT02549976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy to realize within 4 months following inclusion
Study NCT02549976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic MRI
Description: Pelvic MRI to realize within 4 months following inclusion
Study NCT03471728 — intervention group
Intervention type: DRUG
Intervention: linaclotide
Description: Oral
Study NCT03616444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shenbai Granules
Description: In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
Study NCT03616444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenbai Granules
Description: In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
Study NCT01373112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static Spacer
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
Study NCT01373112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Articulating Spacer
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
Study NCT02273271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FLT-PET/CT and DWI-MRI
Description: Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
Study NCT00170313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conducted AF-Response Algorithm (CAFR) On
Description: Algorithm will be enabled.
Study NCT00170313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conducted AF-Response Algorithm (CAFR) Off
Description: Algorithm will be disabled.
Study NCT01953432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
Study NCT01953432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo daily dosing
Study NCT02183805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane,Cyclophosphamide,Carboplatin
Description: High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
Study NCT01632150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Powder for solution, 400-mg vials, for infusion
Study NCT01632150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 50-mg capsules administered orally
Study NCT01632150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
Study NCT01632150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50-mg tablets administered orally
Study NCT05248295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unison speech (vs. solo)
Description: Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.